Related Experiment Videos
Changing outcome of homozygous alpha-thalassemia: cautious optimism
S T Singer1, L Styles, J Bojanowski
1Division of Hematology/Oncology, Children's Hospital, Oakland, California 94609, USA.
Insights
This study details a rare surviving infant with homozygous alpha-thalassemia, highlighting successful management through regular transfusions. Advances in medical interventions offer hope for previously fatal congenital conditions.
Area of Science:
- Genetics
- Hematology
- Pediatrics
Background:
- Homozygous alpha-thalassemia is a severe, typically fatal genetic hemoglobinopathy.
- Long-term survival is exceptionally rare, with limited reported cases.
Observation:
- Presents a case of a surviving infant with homozygous alpha-thalassemia without antenatal intervention.
- The child, now 2.5 years old, exhibits normal growth and development with regular transfusion therapy.
Findings:
- Literature review of Bart hemoglobinopathy survivors shows severe perinatal issues and frequent congenital defects.
- Modern advancements in diagnosis and treatment enable extended survival for infants with severe congenital conditions.
Implications:
- Regular transfusions, chelation therapy, and bone marrow transplantation offer viable long-term management and curative strategies.
- Improved antenatal and postnatal care significantly impacts outcomes for severe congenital disorders.
Abstract:
Only a few long-term survivors of homozygous alpha-thalassemia, a usually fatal condition, have been reported. The authors present a surviving infant with this disorder and discuss the complications, treatments, and implications of this genetic hemoglobinopathy. The child had no antenatal intervention and has been treated with regular transfusions. She has had normal growth and development and is currently 2.5-years-old. A literature review of survivors with Bart hemoglobinopathy reveals an intense perinatal course and a great prevalence of congenital urogenital and limb defects. Advances in antenatal diagnosis, intrauterine intervention, and postnatal treatments have resulted in extended survival of children with congenital defects that until recently were considered invariably fatal. Transfusion and chelation therapy and bone marrow transplantation provide long-term treatment and potential curative options.